‘Convalescent Plasma’- An Effective Treatment Option to Prevent
Emerging nCOVID-19- A Review

Sumel      Ashique; Tahamina      Khatun; Garima      Sahu; Aakash      Upadhyay; Archana      Adhana; Shubneesh      Kumar; Navjot      Sandhu; Nitish      Kumar
Abstract

To date, no accepted therapy exists for treating the emerging infectious disease nCOVID-19 in a safe and effective way. Although various treatment options are under in the developing phase around the world, several studies concerning convalescent plasma (CP) from recovered patients reported promising effects against nCOVID-19 infected critically ill patients nowadays. The therapy showed very few adverse effects, and it helps diminish the viral load when administered at an early stage of infection. Convalescent plasma appears safe for critically ill nCOVID-19 patients by decreasing serum viral loads, and most cases are virus negative after CP transfusion. The convalescent plasma can be good as it has already been utilized to treat previous pandemics like Ebola, influenza, and SARS-CoV infection. In this review article, we pointed out CP's background, rationality, mechanisms, and safety outcomes to treat nCOVID-19 infected patients.
Keywords: Convalescent plasma, nCOVID-19, Previous use in epidemics, clinical trials, Benefits.
Graphical Abstract

[1]
Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ  2020; 368(m1256): m1256.
 [http://dx.doi.org/10.1136/bmj.m1256] [PMID:  32217555]

[2]
World Health Organization.  Available from: https://covid19.who.int [Last accessed on 23 Jan 2021].

[3]
Brown AJ, Won JJ, Graham RL, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res  2019; 169: 104541.
 [http://dx.doi.org/10.1016/j.antiviral.2019.104541] [PMID:  31233808]

[4]
Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med  2017; 9(396): eaal3653.
 [http://dx.doi.org/10.1126/scitranslmed.aal3653] [PMID:  28659436]

[5]
Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquinediphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections: A randomized clinical trial. JAMA Netw Open  2020; 3(4): e208857.
 [http://dx.doi.org/10.1001/jamanetworkopen.2020.8857] [PMID:  32330277]

[6]
U.S Food and Drug.  Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use- [Accessed on 23 Jan 2021].

[7]
Alanagreh LA, Alzoughool F, Atoum M. Risk of using hydroxychloroquine as a treatment of COVID-19. Int J Risk Saf Med  2020; 31(3): 111-6.

[8]
Ripoll JG, van Helmond N, Senefeld JW, et al. Convalescent plasma for infectious diseases: historical framework and use in COVID-19. Clin Microbiol Newsl  2021; 43(4): 23-32.
 [http://dx.doi.org/10.1016/j.clinmicnews.2021.02.001] [PMID:  33564204]

[9]
Florescu DF, Kalil AC, Hewlett AL, et al. Administration of brincidofovir and convalescent plasma in a patient with Ebola virus disease. Clin Infect Dis  2015; 61(6): 969-73.
 [http://dx.doi.org/10.1093/cid/civ395] [PMID:  25991468]

[10]
Zhang J, Xie B, Hashimoto K. Current status of potential therapeutic candidates for the COVID-19 crisis. Brain Behav Immun  2020; 87: 59-73.
 [http://dx.doi.org/10.1016/j.bbi.2020.04.046] [PMID:  32334062]

[11]
Zhou M, Zhang X, Qu J. Coronavirus disease 2019 (COVID-19): A clinical update. Front Med  2020; 14(2): 126-35.
 [http://dx.doi.org/10.1007/s11684-020-0767-8] [PMID:  32240462]

[12]
Marano G, Vaglio S, Pupella S, et al. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus  2016; 14(2): 152-7.
 [PMID:  26674811]

[13]
Khan Z. Karataş Y, Rahman H. Anti COVID-19 drugs: need for more clinical evidence and global action. Adv Ther  2020; 37(6): 2575-9.
 [http://dx.doi.org/10.1007/s12325-020-01351-9] [PMID:  32350686]

[14]
Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect  2004; 10(7): 676-8.
 [http://dx.doi.org/10.1111/j.1469-0691.2004.00956.x] [PMID:  15214887]

[15]
Wong VW, Dai D, Wu AK, Sung JJ. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J  2003; 9(3): 199-201.
 [PMID:  12777656]

[16]
Yeh KM, Chiueh TS, Siu LK, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother  2005; 56(5): 919-22.
 [http://dx.doi.org/10.1093/jac/dki346] [PMID:  16183666]

[17]
Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med  2007; 357(14): 1450-1.
 [http://dx.doi.org/10.1056/NEJMc070359] [PMID:  17914053]

[18]
Xu Z, Zhou J, Huang Y, et al. Efficacy of convalescent plasma for the treatment of severe influenza. Crit Care  2020; 24(1): 469.
 [http://dx.doi.org/10.1186/s13054-020-03189-7] [PMID:  32727526]

[19]
Beigel JH, Tebas P, Elie-Turenne MC, et al. Immune plasma for the treatment of severe influenza: An open-label, multicentre, phase 2 randomised study. Lancet Respir Med  2017; 5(6): 500-11.
 [http://dx.doi.org/10.1016/S2213-2600(17)30174-1] [PMID:  28522352]

[20]
Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis  1999; 179 (Suppl. 1): S18-23.
 [http://dx.doi.org/10.1086/514298] [PMID:  9988160]

[21]
van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med  2016; 374(1): 33-42.
 [http://dx.doi.org/10.1056/NEJMoa1511812] [PMID:  26735992]

[22]
Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infections. Chest  2020; 158(1): e9-e13.
 [http://dx.doi.org/10.1016/j.chest.2020.03.039] [PMID:  32243945]

[23]
Focosi D, Anderson AO, Tang JW, Tuccori M. Convalescent plasma therapy for COVID-19: state of the art. Clin Microbiol Rev  2020; 33(4): e00072-20.
 [http://dx.doi.org/10.1128/CMR.00072-20] [PMID:  32792417]

[24]
Hsu JL, Safdar N. Polyclonal immunoglobulins and hyperimmune globulins in prevention and management of infectious diseases. Infectious Disease Clinics  2011; 25(4): 773-88.
 [http://dx.doi.org/10.1016/j.idc.2011.07.005] [PMID:  22054755]

[25]
Borba M, de Almeida Val F, Sampaio VS, Alexandre MA, Melo GC, Brito M. Chloroquinediphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIbs clinical trial (CloroCovid-19 Study). Med Rxiv  2020; 1-30.

[26]
Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest  2020; 130(4): 1545-8.
 [http://dx.doi.org/10.1172/JCI138003] [PMID:  32167489]

[27]
Drexler M. Institute of Medicine (US). What you need to know about infectious disease Washington. National Academies Press (US) 2010.

[28]
Piyush R, Rajarshi K, Khan R, Ray S. Convalescent plasma therapy: A promising coronavirus disease 2019 treatment strategy. Open Biol  2020; 10(9): 200174.
 [http://dx.doi.org/10.1098/rsob.200174] [PMID:  32898468]

[29]
Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell  2006; 124(4): 849-63.
 [http://dx.doi.org/10.1016/j.cell.2006.02.019] [PMID:  16497593]

[30]
Nicholson LB. The immune system. Essays Biochem  2016; 60(3): 275-301.
 [http://dx.doi.org/10.1042/EBC20160017] [PMID:  27784777]

[31]
Casadevall A, Pirofski LA. A new synthesis for antibody-mediated immunity. Nat Immunol  2011; 13(1): 21-8.
 [http://dx.doi.org/10.1038/ni.2184] [PMID:  22179281]

[32]
Montelongo-Jauregui D, Vila T, Sultan AS, Jabra-Rizk MA. Convalescent serum therapy for COVID-19: A 19th century remedy for a 21st century disease. PLoS Pathog  2020; 16(8): e1008735.
 [http://dx.doi.org/10.1371/journal.ppat.1008735] [PMID:  32785259]

[33]
Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest  2020; 130(6): 2757-65.
 [http://dx.doi.org/10.1172/JCI138745] [PMID:  32254064]

[34]
Ranganathan S, Iyer RN. Convalescent plasma - Is it useful for treating SARS Co-V2 infection? Indian J Med Microbiol  2020; 38(3 & 4): 252-60.
 [http://dx.doi.org/10.4103/ijmm.IJMM_20_358] [PMID:  33154232]

[35]
Langhi DM. Junior, Santis GC, Bordin JO. COVID-19 convalescent plasma transfusion. Hematol Transfus Cell Ther  2020; 42(2): 113-5.
 [http://dx.doi.org/10.1016/j.htct.2020.04.003] [PMID:  32313872]

[36]
Diep BA, Le VT, Badiou C, et al. IVIG-mediated protection against necrotizing pneumonia caused by MRSA. Sci Transl Med  2016; 8(357): 357ra124.
 [http://dx.doi.org/10.1126/scitranslmed.aag1153] [PMID:  27655850]

[37]
Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med  2010; 38(4) (Suppl.): e66-73.
 [http://dx.doi.org/10.1097/CCM.0b013e3181d44c1e] [PMID:  20154602]

[38]
Al‐Riyami AZ, Schäfer R, van den Berg K, et al. Clinical use of convalescent plasma in the covid‐19 pandemic: A transfusion‐focussed gap analysis with recommendations for future research priorities. Vox Sang  2021; 116(1): 88-98.
 [PMID: 32542847]

[39]
Beigel JH, Luke TC. A study in scarlet-convalescent plasma for severe influenza. Crit Care Med  2012; 40(3): 1027-8.
 [http://dx.doi.org/10.1097/CCM.0b013e31823d77c3] [PMID:  22343871]

[40]
Kraft CS, Hewlett AL, Koepsell S, et al. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin Infect Dis  2015; 61(4): 496-502.
 [http://dx.doi.org/10.1093/cid/civ334] [PMID:  25904375]

[41]
Investigational COVID-19 Convalescent Plasma.  Available from: www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-covid-19-convalescent-plasma [Accessed on January 26 2021].

[42]
Rojas M, Rodríguez Y, Monsalve DM, et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev  2020; 19(7): 102554.
 [http://dx.doi.org/10.1016/j.autrev.2020.102554] [PMID:  32380316]

[43]
Samad N, Sodunke TE, Banna HA, et al. Convalescent plasma therapy for management of covid-19: perspectives and deployment in the current global pandemic. Risk Manag Healthc Policy  2020; 13: 2707-28.
 [http://dx.doi.org/10.2147/RMHP.S281388] [PMID:  33262668]

[44]
Baveja UK. Diagnosis and management of HIV/AIDS: A clinician’s perspective. BI Publications Pvt Ltd 2004.

[45]
Benjamin RJ. Bacterial contamination of blood components. Rossi's Principles of Transfusion Medicine, Eds Simon TL, 
McCullough J, Snyder EL, Solheim BG, Trauss RGS.  John Wiley & Sons, Ltd. 2016; pp. 608-19.
 [http://dx.doi.org/10.1002/9781119013020.ch53]

[46]
Maskens C, Downie H, Wendt A, et al. Hospital-based transfusion error tracking from 2005 to 2010: identifying the key errors threatening patient transfusion safety. Transfusion  2014; 54(1): 66-73.
 [http://dx.doi.org/10.1111/trf.12240] [PMID:  23672511]

[47]
Crookston KP, Koenig SC, Reyes MD. Transfusion reaction identification and management at the bedside. J Infus Nurs  2015; 38(2): 104-13.
 [http://dx.doi.org/10.1097/NAN.0000000000000097] [PMID:  25723832]

[48]
Chaurasia R, Zaman S, Das B, Chatterjee K. Screening donated blood for transfusion transmitted infections by serology along with NAT and response rate to notification of reactive results: An Indian experience. J Blood Transfus  2014; 2014: 412105.

[49]
Allain JP, Goodrich R. Pathogen reduction of whole blood: utility and feasibility. Transfus Med  2017; 27(5) (Suppl. 5): 320-6.
 [http://dx.doi.org/10.1111/tme.12456] [PMID:  28875531]

[50]
Eder A, Goldman M, Rossmann S, Waxman D, Bianco C. Selection criteria to protect the blood donor in North America and Europe: past (dogma), present (evidence), and future (hemovigilance). Transfus Med Rev  2009; 23(3): 205-20.
 [http://dx.doi.org/10.1016/j.tmrv.2009.03.003] [PMID:  19539875]

[51]
World Health Organization. Blood donor selection: guidelines on assessing donor suitability for blood donation World Health Organization.  2012. Available from: https://apps.who.int/iris/handle/10665/76724

[52]
Flesland Ø, Osselton WJC. Donor vigilance and hemovigilance. Rossi's Principles of Transfusion Medicine, Eds Simon TL, 
McCullough J, Snyder EL, Solheim BG, Trauss RGS .  John Wiley & Sons, Ltd. 2016; pp. 58-68.
 [http://dx.doi.org/10.1002/9781119013020.ch06]

[53]
Roberts DJ, Miflin G, Estcourt L. Convalescent plasma for COVID‐19: Back to the future. Transfus Med  2020; 30(3): 174-6.

[54]
Casadevall A, Joyner MJ, Pirofski LA. A randomized trial of convalescent plasma for COVID-19-potentially hopeful signals. JAMA  2020; 324(5): 455-7.
 [http://dx.doi.org/10.1001/jama.2020.10218] [PMID:  32492105]

[55]
Zeng H, Wang D, Nie J, et al. The efficacy assessment of convalescent plasma therapy for COVID-19 patients: A multi-center case series. Signal Transduct Target Ther  2020; 5(1): 219.
 [http://dx.doi.org/10.1038/s41392-020-00329-x] [PMID:  33024082]

[56]
Khulood D, Adil MS, Sultana R. Nimra. Convalescent plasma appears efficacious and safe in COVID-19. Ther Adv Infect Dis  2020; 7: 2049936120957931.
 [http://dx.doi.org/10.1177/2049936120957931] [PMID:  33062267]

[57]
Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent plasma antibody levels and the risk of death from COVID-19. N Engl J Med  2021; 384(11): 1015-27.
 [http://dx.doi.org/10.1056/NEJMoa2031893] [PMID:  33523609]

[58]
Mahase E. Covid-19: US approve emergency use of convalescent plasma despite warnings over lack of evidence. BMJ  2020; 370: m3327.

[59]
Zheng K, Liao G, Lalu MM, Tinmouth A, Fergusson DA, Allan DS. A scoping review of registered clinical trials of convalescent plasma for COVID-19 and a Framework for Accelerated Synthesis of Trial Evidence (FAST Evidence). Transfus Med Rev  2020; 34(3): 158-64.
 [http://dx.doi.org/10.1016/j.tmrv.2020.06.005] [PMID:  32771272]

[60]
Joyner MJ, Bruno KA, Klassen SA, et al. Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients. Mayo Clin Proc  2020; 95(9): 1888-97.

[61]
Schwartz SP, Thompson P, Smith M, et al. Convalescent plasma therapy in four critically ill pediatric patients with coronavirus disease 2019: A case series. Crit Care Explor  2020; 2(10): e0237.
 [http://dx.doi.org/10.1097/CCE.0000000000000237] [PMID:  33063037]

[62]
Ye M, Fu D, Ren Y, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol  2020; 92(10): 1890-901.
 [http://dx.doi.org/10.1002/jmv.25882] [PMID:  32293713]

[63]
Korley FK, Durkalski-Mauldin V, Yeatts SD, et al. Early convalescent plasma for high-risk outpatients with COVID-19. N Engl J Med  2021; 385(21): 1951-60.
 [http://dx.doi.org/10.1056/NEJMoa2103784] [PMID:  34407339]

[64]
Tamburello A, Marando M. Immunoglobulins or convalescent plasma to tackle COVID-19: buying time to save lives–current situation and perspectives. Swiss Med Wkly  2020; 150: w20264.

[65]
Zhang L, Pang R, Xue X, et al. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19. Aging (Albany NY)  2020; 12(8): 6536-42.
 [http://dx.doi.org/10.18632/aging.103102] [PMID:  32320384]

[66]
Lu CL, Murakowski DK, Bournazos S, et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science  2016; 352(6288): 1001-4.
 [http://dx.doi.org/10.1126/science.aaf1279] [PMID:  27199430]

[67]
Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA  2020; 117(17): 9490-6.
 [http://dx.doi.org/10.1073/pnas.2004168117] [PMID:  32253318]

[68]
Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol  2020; 92(9): 1475-83.
 [http://dx.doi.org/10.1002/jmv.25961] [PMID:  32356910]

[69]
Gharbharan A, Jordans CC, Geurtsvan KC, et al. Convalescent plasma for COVID-19. A randomized clinical trial. MEDRxiv 2020.

[70]
Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial. JAMA  2020; 324(5): 460-70.
 [http://dx.doi.org/10.1001/jama.2020.10044] [PMID:  32492084]

[71]
Avendano-Sola C, Ramos-Martinez A, Munez-Rubio E, Ruiz-Antoran B. Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial. MedRxiv 2020.

[72]
Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentrerandomised controlled trial (PLACID Trial). BMJ  2020; 371: m3939.

[73]
Olivares-Gazca JC, Priesca-Marín JM, Ojeda-Laguna M, et al. Infusion of convalescent plasma is associated with clinical improvement in critically ill patients with COVID-19: A pilot study. Rev Invest Clin  2020; 72(3): 159-64.
 [http://dx.doi.org/10.24875/RIC.20000237] [PMID:  32584322]

[74]
Liu ST, Lin HM, Baine I, et al. Convalescent plasma treatment of severe COVID-19: A matched control study. MedRxiv 2020.
 [http://dx.doi.org/10.1101/2020.05.20.20102236]

[75]
Zeng QL, Yu ZJ, Gou JJ, et al. Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. J Infect Dis  2020; 222(1): 38-43.
 [http://dx.doi.org/10.1093/infdis/jiaa228] [PMID:  32348485]

[76]
Donato M, Park S, Baker M, et al. Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma: A prospective study. MedRxiv 2020.
 [http://dx.doi.org/10.1101/2020.07.20.20156398]

[77]
Salazar MR, Gonzalez SE, Regairaz L, et al. Effect of convalescent plasma on mortality in patients with COVID-19 pneumonia. Med Rxiv 2020.

[78]
Vickers NJ. Animal communication: when I’m calling you, will you answer too. Curr Biol  2017; 27(14): R713-5.
 [http://dx.doi.org/10.1016/j.cub.2017.05.064] [PMID:  28743020]

[79]
Rasheed AM, Fatak DF, Hashim HA, Maulood MF, Kabah KK, Abdulamir AS. The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. MedRxiv 2020.

[80]
Xia X, Li K, Wu L, et al. Improved clinical symptoms and mortality on severe/critical COVID-19 patients utilizing convalescent plasma transfusion. Blood  2020; 136(6): 755-9.
 [http://dx.doi.org/10.1182/blood.2020007079]

[81]
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell  2020; 181(2): 281-292.e6.
 [http://dx.doi.org/10.1016/j.cell.2020.02.058] [PMID:  32155444]

[82]
Valentini R, Dupont J, Fernandez J, et al. Convalescent plasma as potential therapy for severe COVID-19 pneumonia. MedRxiv 2020.
 [http://dx.doi.org/10.1101/2020.09.01.20184390]

[83]
Parida SK, Axelsson-Robertson R, Rao MV, et al. Totally drug-resistant tuberculosis and adjunct therapies. J Intern Med  2015; 277(4): 388-405.
 [http://dx.doi.org/10.1111/joim.12264] [PMID:  24809736]

[84]
Jin C, Gu J, Yuan Y, et al. Treatment of 6 COVID-19 patients with convalescent plasma. MedRxiv 2020.
 [http://dx.doi.org/10.1101/2020.05.21.20109512]

[85]
Jiang J, Miao Y, Zhao Y, et al. Convalescent plasma therapy: Helpful treatment of COVID-19 in a kidney transplant recipient presenting with severe clinical manifestations and complex complications. Clin Transplant  2020; 34(9): e14025.
 [http://dx.doi.org/10.1111/ctr.14025] [PMID:  32602952]

[86]
Figlerowicz M, Mania A, Lubarski K, et al. First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia. Transfus Apheresis Sci  2020; 59(5): 102866.
 [http://dx.doi.org/10.1016/j.transci.2020.102866] [PMID:  32636116]

[87]
Lee E, Jeong K, Lee J, et al. Clinical and Laboratory Findings of Barley Allergy in Korean Children: A Single Hospital Based Retrospective Study. J Korean Med Sci  2020; 35(3): e23.
 [http://dx.doi.org/10.3346/jkms.2020.35.e23] [PMID:  31950778]

[88]
Diorio C, Anderson EM, McNerney KO, et al. Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome. Pediatr Blood Cancer  2020; 67(11): e28693.
 [http://dx.doi.org/10.1002/pbc.28693] [PMID:  32885904]

[89]
Ouyang J, Isnard S, Lin J, et al. Convalescent plasma: the relay baton in the race for coronavirus disease 2019 treatment. Front Immunol  2020; 11: 570063.
 [http://dx.doi.org/10.3389/fimmu.2020.570063] [PMID:  33072111]

[90]
Bloch EM. Convalescent plasma to treat COVID-19. Blood  2020; 136(6): 654-5.
 [http://dx.doi.org/10.1182/blood.2020007714] [PMID:  32761219]

[91]
Joyner MJ, Wright RS, Fairweather D, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest  2020; 130(9): 4791-7.
 [http://dx.doi.org/10.1172/JCI140200] [PMID:  32525844]

[92]
Wooding DJ, Bach H. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks. Clin Microbiol Infect  2020; 26(10): 1436-46.
 [http://dx.doi.org/10.1016/j.cmi.2020.08.005] [PMID:  32791241]

[93]
US National Institutes of Health. National Library of Medicine: Clinical Trials. gov. Effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment.  Available from: https://clinicaltrials.gov/ct2/show/NCT01790152

[94]
National Library of Medicine: Clinical Trials. gov.  Available from: https://www.clinicaltrials.gov/ct2/results?cond=Corona+virus&term=Convalescent+plasma&cntry=&state=&city=&dist [Accessed on January 25 2021].

[95]
Vanderwerf JD, Kumar MA. Management of neurologic complications of coagulopathies. Handb Clin Neurol  2017; 141: 743-64.
 [http://dx.doi.org/10.1016/B978-0-444-63599-0.00040-5] [PMID:  28190445]

[96]
Iba T, Levy JH, Levi M, Connors JM, Thachil J. Coagulopathy of coronavirus disease 2019. Crit Care Med  2020; 48(9): 1358-64.
 [http://dx.doi.org/10.1097/CCM.0000000000004458] [PMID:  32467443]

[97]
Miesbach W, Makris M. COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clin Appl Thromb Hemost  2020; 26: 1076029620938149.
 [http://dx.doi.org/10.1177/1076029620938149] [PMID:  32677459]

[98]
Levi M, Iba T. COVID-19 coagulopathy: is it disseminated intravascular coagulation. Intern Emerg Med  2021; 16(2): 309-2.
 [PMID:  33368021]

[99]
Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. Am J Hematol  2020; 95(7): 834-47.
 [http://dx.doi.org/10.1002/ajh.25829] [PMID:  32282949]

[100]
Yu HH, Qin C, Chen M, Wang W, Tian DS. D-dimer level is associated with the severity of COVID-19. Thromb Res  2020; 195: 219-25.
 [http://dx.doi.org/10.1016/j.thromres.2020.07.047] [PMID:  32777639]

[101]
Becker RC. COVID-19 update: COVID-19-associated coagulopathy. J Thromb Thrombolysis  2020; 50(1): 54-67.
 [http://dx.doi.org/10.1007/s11239-020-02134-3] [PMID:  32415579]

[102]
Garraud O, Heshmati F, Pozzetto B, et al. Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow. Transfusion Clinique etBiologique  2016; 23(1): 39-44.
 [http://dx.doi.org/10.1016/j.tracli.2015.12.003]

[103]
Lünemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology--mode of action and clinical efficacy. Nat Rev Neurol  2015; 11(2): 80-9.
 [http://dx.doi.org/10.1038/nrneurol.2014.253] [PMID:  25561275]

[104]
Bilgin YM, Brand A. Transfusion-related immunomodulation: A second hit in an inflammatory cascade? Vox Sang  2008; 95(4): 261-71.
 [http://dx.doi.org/10.1111/j.1423-0410.2008.01100.x] [PMID:  19138255]

[105]
Refaai MA, Blumberg N. Transfusion immunomodulation from a clinical perspective: An update. Expert Rev Hematol  2013; 6(6): 653-63.
 [http://dx.doi.org/10.1586/17474086.2013.850026] [PMID:  24168641]

[106]
Psaltopoulou T, Sergentanis TN, Pappa V, et al. The emerging role of convalescent plasma in the treatment of COVID-19. HemaSphere  2020; 4(3): e409.
 [http://dx.doi.org/10.1097/HS9.0000000000000409] [PMID:  32647807]

[107]
Mansourabadi AH, Sadeghalvad M, Mohammadi-Motlagh HR, Rezaei N. The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19. Life Sci  2020; 258: 118185.
 [http://dx.doi.org/10.1016/j.lfs.2020.118185] [PMID:  32750438]

[108]
Sharun K, Tiwari R, Iqbal Yatoo M, et al. Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: Advances and prospects. Expert Opin Biol Ther  2020; 20(9): 1033-46.
 [http://dx.doi.org/10.1080/14712598.2020.1796963] [PMID:  32744917]

[109]
van Griensven J, Edwards T, Gallian P. Convalescent plasma for ebola virus disease. N Engl J Med  2016; 374(25): 2500.
 [PMID:  27332913]

[110]
Lewis GK, Pazgier M, Evans DT, et al. Beyond viral neutralization. AIDS Res Hum Retroviruses  2017; 33(8): 760-4.
 [http://dx.doi.org/10.1089/aid.2016.0299] [PMID:  28084796]

[111]
Anand SP, Finzi A. Understudied factors influencing Fc-Mediated immune responses against viral infections. Vaccines (Basel)  2019; 7(3): 103.
 [http://dx.doi.org/10.3390/vaccines7030103] [PMID:  31480293]

[112]
Salazar E, Perez KK, Ashraf M, et al. Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma. Am J Pathol  2020; 190(8): 1680-90.
 [http://dx.doi.org/10.1016/j.ajpath.2020.05.014] [PMID:  32473109]

[113]
Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis  2020; 20(4): 398-400.
 [http://dx.doi.org/10.1016/S1473-3099(20)30141-9] [PMID:  32113510]

[114]
Dalager-Pedersen M, Bodilsen J. Thromboprophylaxis for medical inpatients with coronavirus disease 2019. Clin Microbiol Infect  2020; 26(9): 1125-6.
 [http://dx.doi.org/10.1016/j.cmi.2020.05.021] [PMID:  32454190]

[115]
Kumar VG, Jeyanthi V, Ramakrishnan S. A short review on antibody therapy for COVID-19. New Microbes New Infect  2020; 35: 100682.
 [http://dx.doi.org/10.1016/j.nmni.2020.100682] [PMID:  32313660]

[116]
da Silva TJA. Convalescent plasma: A possible treatment of COVID-19 in India. Med J Armed Forces India  2020; 15(2): 236-7.
 [http://dx.doi.org/10.1016/j.mjafi.2020.04.006]

[117]
Alzoughool F, Alanagreh LA. Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19. Int J Risk Saf Med  2020; 13: 1-5.

[118]
Iyer M, Jayaramayya K, Subramaniam MD, et al. COVID-19: An update on diagnostic and therapeutic approaches. BMB Rep  2020; 53(4): 191-205.
 [http://dx.doi.org/10.5483/BMBRep.2020.53.4.080] [PMID:  32336317]

[119]
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA  2020; 323(13): 1239-42.
 [http://dx.doi.org/10.1001/jama.2020.2648] [PMID:  32091533]

[120]
Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis  2005; 24(1): 44-6.
 [http://dx.doi.org/10.1007/s10096-004-1271-9] [PMID:  15616839]

[121]
Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol  2020; 5(10): 1185-91.
 [http://dx.doi.org/10.1038/s41564-020-00789-5] [PMID:  32908214]

[122]
Natarajan H, Crowley AR, Butler SE, et al. SARS-CoV-2 antibody signatures robustly predict diverse antiviral functions relevant for convalescent plasma therapy. Med Rxiv 2020.

[123]
Casadevall A, Pirofski LA. Antibody-mediated regulation of cellular immunity and the inflammatory response. Trends Immunol  2003; 24(9): 474-8.
 [http://dx.doi.org/10.1016/S1471-4906(03)00228-X] [PMID:  12967670]

[124]
Pathak EB. Convalescent plasma is ineffective for COVID-19. BMJ  2020; 371: m4072.
 [http://dx.doi.org/10.1136/bmj.m4072]

[125]
Chen JW, Chen JM. Potential of live pathogen vaccines for defeating the COVID-19 pandemic: History and mechanism. J Med Virol  2020; 92(9): 1469-74.
 [http://dx.doi.org/10.1002/jmv.25920] [PMID:  32320059]

[126]
Zhao Q, He Y. Challenges of convalescent plasma therapy on COVID-19. J Clin Virol  2020; 127: 104358.
 [http://dx.doi.org/10.1016/j.jcv.2020.104358] [PMID:  32305026]

[127]
Ahn JY, Sohn Y, Lee SH, et al. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J Korean Med Sci  2020; 35(14): e149.
 [http://dx.doi.org/10.3346/jkms.2020.35.e149] [PMID:  32281317]

[128]
Pouladzadeh M, Safdarian M, Eshghi P, et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Intern Emerg Med  2021; 16(8): 2181-91.
 [http://dx.doi.org/10.1007/s11739-021-02734-8] [PMID:  33837906]

[129]
Vieillard V, Astier A, Sauzay C, Paul M. One-month stability study of a biosimilar of infliximab (Remsima®) after dilution and storage at 4C and 25C. Anns Pharm Franc  2017; 75(1): 17-29.

[130]
González-García J, Gutiérrez-Nicolás F, Nazco-Casariego GJ, Viña-Romero MM. Long-term stability of trastuzumab in plasma and whole blood samples stored under different conditions. Farmaciahospitalaria  2019; 43(2): 50-2.

[131]
Stadlbauer D, Baine I, Amanat F, et al. Anti-SARS-CoV-2 spike antibodies are stable in convalescent plasma when stored at 4° Celsius for at least 6 weeks. Transfusion  2020; 60(10): 2457-9.
 [http://dx.doi.org/10.1111/trf.16047] [PMID:  32798271]

[132]
Tonn T, Corman VM, Johnsen M, et al. Stability and neutralising capacity of SARS-CoV-2-specific antibodies in convalescent plasma. Lancet Microbe  2020; 1(2): e63.
 [http://dx.doi.org/10.1016/S2666-5247(20)30037-9] [PMID:  32835332]

[133]
Mukhra R, Krishan K, Kanchan T. Agony of the laborers and daily wagers during the COVID-19 induced lockdown in India. Acta Bio Medica  2020; 91(4)

[134]
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA  2020; 323(18): 1824-36.
 [http://dx.doi.org/10.1001/jama.2020.6019] [PMID:  32282022]

[135]
Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: The reality and challenges. J Microbiol Immunol Infect  2020; 53(3): 436-43.
 [http://dx.doi.org/10.1016/j.jmii.2020.03.034] [PMID:  32307245]

[136]
Verma HK, Merchant N, Verma MK, et al. Current updates on the European and WHO registered clinical trials of coronavirus disease 2019 (COVID-19). Biomed J  2020; 43(5): 424-33.
 [http://dx.doi.org/10.1016/j.bj.2020.07.008] [PMID:  32792167]

[137]
Saadah NH, van Hout FMA, Schipperus MR, et al. Comparing transfusion reaction rates for various plasma types: A systematic review and meta-analysis/regression. Transfusion  2017; 57(9): 2104-14.
 [http://dx.doi.org/10.1111/trf.14245] [PMID:  28766723]

[138]
Accorsi P, Berti P, de Angelis V, De Silvestro G, Mascaretti L, Ostuni A. Italian Society for Transfusion Medicine Immunohaematology (SIMTI) Italian Society for Hemapheresis cell Manipulation (SIdEM). Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19. Transfus Apheresis Sci  2020; 59(4): 102817.
 [http://dx.doi.org/10.1016/j.transci.2020.102817]

[139]
Zhao Q, He Y. Application of convalescent plasma therapy on novel coronavirus infection. Zhonghua Jie He He Hu Xi Za Zhi  2020; 43(5): 409-13.
 [PMID:  32450629]

[140]
Eckhardt CM, Cummings MJ, Rajagopalan KN, et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials  2020; 21(1): 1-3.
 [http://dx.doi.org/10.1186/s13063-020-04504-x] [PMID:  31898511]

[141]
Pyrc K, Bosch BJ, Berkhout B, et al. Inhibition of human coronavirus NL63 infection at early stages of the replication cycle. Antimicrob Agents Chemother  2006; 50(6): 2000-8.
 [http://dx.doi.org/10.1128/AAC.01598-05] [PMID:  16723558]

[142]
Shoemaker CJ, Schornberg KL, Delos SE, et al. Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection. PLoS One  2013; 8(2): e56265.
 [http://dx.doi.org/10.1371/journal.pone.0056265] [PMID:  23441171]

[143]
Bleibtreu A, Jaureguiberry S, Houhou N, et al. Clinical management of respiratory syndrome in patients hospitalized for suspected Middle East respiratory syndrome coronavirus infection in the Paris area from 2013 to 2016. BMC Infect Dis  2018; 18(1): 331-40.
 [http://dx.doi.org/10.1186/s12879-018-3223-5] [PMID:  30012113]

[144]
Tan EL, Ooi EE, Lin CY, et al. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis  2004; 10(4): 581-6.
 [http://dx.doi.org/10.3201/eid1004.030458] [PMID:  15200845]

[145]
Al-Abdely HM, Midgley CM, Alkhamis AM, et al. Middle East respiratory syndrome coronavirus infection dynamics and antibody responses among clinically diverse patients, Saudi Arabia. Emerg Infect Dis  2019; 25(4): 753-66.
 [http://dx.doi.org/10.3201/eid2504.181595] [PMID:  30882305]

[146]
Saeed AA, Abedi GR, Alzahrani AG, et al. Surveillance and testing for Middle East respiratory syndrome coronavirus, Saudi Arabia, April 2015- February 2016. Emerg Infect Dis  2017; 23(4): 682-5.
 [http://dx.doi.org/10.3201/eid2304.161793] [PMID:  28322710]

[147]
Sumel A, Navjot SK, Sk HN. Koley Kartick, “a recent update on therapeutics to treat emerging n-COVID 19: a review. Coronaviruses  2021; 2(7): e250621188724.
 [http://dx.doi.org/10.2174/2666796701999201204123259]

[148]
Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med  2013; 19(10): 1313-7.
 [http://dx.doi.org/10.1038/nm.3362] [PMID:  24013700]

[149]
Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: A retrospective cohort study. Lancet Infect Dis  2014; 14(11): 1090-5.
 [http://dx.doi.org/10.1016/S1473-3099(14)70920-X] [PMID:  25278221]

[150]
Shalhoub S, Farahat F, Al-Jiffri A, et al. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: A retrospective study. J Antimicrob Chemother  2015; 70(7): 2129-32.
 [http://dx.doi.org/10.1093/jac/dkv085] [PMID:  25900158]

[151]
Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio  2018; 9(2): e00221-18.
 [http://dx.doi.org/10.1128/mBio.00221-18] [PMID:  29511076]

[152]
Abd-Elsalam S, Salama M, Soliman S, et al. Remdesivir efficacy in COVID-19 treatment: A randomized controlled trial. Am J Trop Med Hyg  2021; 106(3): 886-90.
 [http://dx.doi.org/10.4269/ajtmh.21-0606] [PMID:  34649223]

[153]
Taylor R, Kotian P, Warren T, et al. BCX4430 - A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. J Infect Public Health  2016; 9(3): 220-6.
 [http://dx.doi.org/10.1016/j.jiph.2016.04.002] [PMID:  27095300]

[154]
Peters HL, Jochmans D, de Wilde AH, et al. Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity. Bioorg Med Chem Lett  2015; 25(15): 2923-6.
 [http://dx.doi.org/10.1016/j.bmcl.2015.05.039] [PMID:  26048809]

[155]
Yamamoto N, Yang R, Yoshinaka Y, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun  2004; 318(3): 719-25.
 [http://dx.doi.org/10.1016/j.bbrc.2004.04.083] [PMID:  15144898]

[156]
Oldfield V, Plosker GL. Lopinavir/ritonavir: A review of its use in the management of HIV infection. Drugs  2006; 66(9): 1275-99.
 [http://dx.doi.org/10.2165/00003495-200666090-00012] [PMID:  16827606]

[157]
Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: A multicentre retrospective matched cohort study. Hong Kong Med J  2003; 9(6): 399-406.
 [PMID:  14660806]

[158]
Jin YH, Cai L, Cheng ZS, et al. Evidence-based medicine chapter of china international exchange and promotive association for medical and health care (CPAM). A rapid advice guideline for the diagnosis and treatment of 2019; 1-23.

[159]
El-Bendary M, Abd-Elsalam S, Elbaz T, et al. Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: A multicenter Egyptian study. Expert Rev Anti Infect Ther  2022; 20(2): 291-5.
 [PMID:  34225541]

[160]
Dabbous HM, Abd-Elsalam S, El-Sayed MH, et al. Efficacy of favipiravir in COVID-19 treatment: A multi-center randomized study. Arch Virol  2021; 166(3): 949-54.
 [http://dx.doi.org/10.1007/s00705-021-04956-9] [PMID:  33492523]

[161]
Kuki Á, Nagy L, Zsuga M, Kéki S. Fast identification of phthalic acid esters in poly (vinyl chloride) samples by direct analysis in real time (DART) tandem mass spectrometry. Int J Mass Spectrom  2011; 303(2-3): 225-8.
 [http://dx.doi.org/10.1016/j.ijms.2011.02.011]

[162]
Ghasemnejad-Berenji M, Pashapour S. Favipiravir and COVID-19: A simplified summary. Drug Res (Stuttg)  2021; 71(3): 166-70.
 [http://dx.doi.org/10.1055/a-1296-7935] [PMID:  33176367]

[163]
Saijo M, Morikawa S, Fukushi S, et al. Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus. Antiviral Res  2005; 66(2-3): 159-63.
 [http://dx.doi.org/10.1016/j.antiviral.2005.01.003] [PMID:  15911031]

[164]
Greenough TC, Babcock GJ, Roberts A, et al. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis  2005; 191(4): 507-14.
 [http://dx.doi.org/10.1086/427242] [PMID:  15655773]

[165]
Shen C, Wang Z, Zhao F, et al. posting date. Treatment of 5 critically ill patients with COVID19 with convalescent plasma. JAMA  2020; 323(16): 1582.
 [http://dx.doi.org/10.1001/jama.2020.4783]

[166]
Abd-Elsalam S, Noor RA, Badawi R, et al. Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study. J Med Virol  2021; 93(10): 5833-8.
 [http://dx.doi.org/10.1002/jmv.27122] [PMID:  34076901]

[167]
Liu STH, Lin HM, Baine I, et al. Convalescent plasma treatment of severe COVID-19: A propensity score-matched control study. Nat Med  2020; 26(11): 1708-13.
 [http://dx.doi.org/10.1038/s41591-020-1088-9] [PMID:  32934372]

[168]
Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol  2020; 214: 108393.
 [http://dx.doi.org/10.1016/j.clim.2020.108393] [PMID:  32222466]

[169]
Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov  2020; 19(3): 149-50.
 [http://dx.doi.org/10.1038/d41573-020-00016-0] [PMID:  32127666]

[170]
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res  2020; 178: 104787.

[171]
Ng OW, Tan YJ. Understanding bat SARS-like coronaviruses for the preparation of future coronavirus outbreaks - Implications for coronavirus vaccine development. Hum Vaccin Immunother  2017; 13(1): 186-9.
 [http://dx.doi.org/10.1080/21645515.2016.1228500] [PMID:  27644155]

[172]
Abd-Elsalam S, Soliman S, Esmail ES, et al. Do zinc supplements enhance the clinical efficacy of hydroxychloroquine?: A randomized, multicenter trial. Biol Trace Elem Res  2021; 199(10): 3642-6.
 [http://dx.doi.org/10.1007/s12011-020-02512-1] [PMID:  33247380]

[173]
Szarpak L, Pruc M, Gasecka A, et al. Should we supplement zinc in COVID-19 patients? Evidence from a meta-analysis. Pol Arch Intern Med  2021; 131(9): 802-7.
 [http://dx.doi.org/10.20452/pamw.16048] [PMID:  34180610]

[174]
Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA  2020; 323(16): 1561-2.
 [http://dx.doi.org/10.1001/jama.2020.4940] [PMID:  32219429]

[175]
Leider JP, Brunker PA, Ness PM. Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product? Transfusion  2010; 50(6): 1384-98.
 [http://dx.doi.org/10.1111/j.1537-2995.2010.02590.x] [PMID:  20158681]
Cite As
Infectious Disorders - Drug Targets

‘Convalescent Plasma’- An Effective Treatment Option to Prevent Emerging nCOVID-19- A Review

Abstract

Graphical Abstract
